Life Sciences Tools and Services
Company Overview of Gallus Biopharmaceuticals, LLC
Gallus Biopharmaceuticals, LLC provides biopharmaceutical contract development and manufacturing services. The company offers process development, analytical method development, process validation, quality/regulatory, cGMP manufacturing, fill/finish, and project management services, as well as stability, cell banking, and storage services. It also manufactures mammalian biopharmaceutical products. The company was founded in 2010 and is headquartered in St. Louis, Missouri with a location in Princeton, New Jersey. As of September 29, 2014, Gallus Biopharmaceuticals, LLC operates as a subsidiary of DPx Holdings B.V.
4766 LaGuardia Drive
St. Louis, MO 63134-3117
Founded in 2010
Key Executives for Gallus Biopharmaceuticals, LLC
Founder, Chief Executive Officer, President and Director
Founder and Chief Financial Officer
Chief Manufacturing Officer
Senior Director of Human Resources
Senior Vice President of Business Development
Compensation as of Fiscal Year 2014.
Gallus Biopharmaceuticals, LLC Key Developments
Gallus Biopharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:45 PM
Sep 10 14
Gallus Biopharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:45 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Gallus Biopharmaceuticals, LLC Presents at BIO-Europe 2014, Nov-04-2014 05:15 PM
Sep 3 14
Gallus Biopharmaceuticals, LLC Presents at BIO-Europe 2014, Nov-04-2014 05:15 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.
Gallus BioPharmaceuticals, LLC Enters Cell Line Optimization and Manufacturing Agreement with Omni Bio Pharmaceutical, Inc
Apr 29 14
Gallus BioPharmaceuticals, LLC and Omni Bio Pharmaceutical, Inc. jointly announced finalization of a multi-stage manufacturing services agreement. The agreement includes cell line optimization, analytical development and manufacturing scale-up activities for Omni Bio's leading AAT Fc fusion protein with the goal of providing cGMP product to support animal toxicology studies and early clinical trials of the molecule. Under the agreement, Omni Bio has selected the commercially available CHOZN(R) GS Cell line as the expression system. In addition, SAFC(R) will perform the cell line development and safety testing services, in conjunction with Gallus' overall management of the process development and manufacturing services program for Omni Bio. AAT is the most abundant circulating serine protease inhibitor in the body and an acute phase reactant. Systemic deficiency in AAT due to genetic mutations can result in debilitating liver failure and chronic lung disease such as emphysema. Lifelong treatment with plasma-derived AAT, intravenously administered, is indicated for such patients. Recent evidence suggests that AAT plays an important role in modulating immunity, inflammation and apoptosis. AAT protects various cell types from cell death, inhibits caspases-1 and -3 activity and has been shown to be effective in a wide variety of animal models of human disease, including diabetes, graft versus host disease (rejection reactions following bone marrow or other transplantation procedures), refractory gout, myocardial infarction and inflammatory bowel disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 27, 2014